Varubi Approved as an Antiemetic
September 1, 2015 – The U.S. Food and Drug Administration (FDA) granted Tesaro, Inc. approval for Varubi (rolapitant) as an antiemetic in the control of nausea and vomiting (emesis) by blocking receptors for substance P/neurokinin 1 (NK-1). Varubi is indicated to prevent delayed nausea and vomiting for adults undergoing emetogenic (vomit-causing) chemotherapy. About half of patients receiving some type of chemotherapy experience chemotherapy-induced nausea and vomiting (CINV) between 25 hours and 120 hours after getting the chemo. Varubi will be used along with a corticosteroid, dexamethasone, and a 5-HT3 blocker, such as granisetron or ondansetron to prevent such delayed CINV. Recommended dosing for Varubi is 180mg (two 90mg tablets) to be taken two hours or less before each cycle of chemotherapy begins.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.